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Ethical conduct in human subjects research is primarily enforced by the federal 
government through regulations from agencies like the Food & Drug Administration or 
Department of Health and Human Services and the U.S. Congress. Throughout the 20th 
century, widely publicized events like the Tuskegee syphilis scandal and the 
diethylstilbestrol tragedy provided the impetus to create or improve research ethics 
regulations. However, increased regulation results in decreased probability of future 
triggering events from occurring; thus, the primary driver of research ethics policy is 
destined to fade over time. As less extreme triggering events fail to push legislators into 
action, research ethics policy will progress at an unacceptably slow pace. The field of 
bioethics has yet to establish a sustainable advocacy infrastructure meant to advance the 
recommendations of bioethicists in the field, but doing so is necessary to fill the void in 
political momentum left by extreme triggering events. Through a literature review and 
analysis of primary government documents, I evidence current dependence on triggering 
events and advocate for the creation of a new driver of progress, namely, a nonprofit 
research ethics advocacy organization. This entity would be able to provide proactive 
research ethics policy recommendations, thus allowing the federal government to better 
address issues in this area when triggering events do arise. Existing bioethics academic 
centers and professional organizations, such as the Hastings Center or the American 
Society for Bioethics and Humanities (ASBH), are best prepared to develop an advocacy 
group. Current policy stakeholders in the research ethics sphere are either institutions of 
higher education or medical interest groups, both of which have a broad array of interests 
that prevent them from regularly prioritizing improved ethics regulations in their advocacy 
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efforts. A shift in this niche policy area is necessary in order to continue the push to 




For every policy issue, there is a reason why it caught the attention of policymakers. 
When thinking about major issues like healthcare and taxation, it is relatively easy to surmise the 
logic; they affect the daily lives of nearly every American citizen, and thus factor significantly 
into voters’ considerations of political candidates. However, essentially any part of life has the 
potential to garner legislative attention, should the proper conditions fall into place. What, then, 
is necessary for a policy issue to get on the political agenda? In the case of research ethics, issues 
typically come to the fore as a byproduct of newsworthy events that concisely and abruptly 
explain a problem to a wide audience. With the exception of such circumstances, research ethics 
is a technical and esoteric field that few laypeople and, for that matter, policymakers, understand. 
Unfortunately, this knowledge gap makes creating well-crafted laws and regulations difficult for 
policymakers in the wake of triggering events demanding legislative attention.    
Research ethics is one of three main branches within the academic field of bioethics. 
Accompanied by medical ethics and public health ethics, it addresses the moral components of 
how researchers in various fields conduct their work. It is at this point that the scope of bioethics 
may become ambiguous, as research ethics may be understood as the ethics of any research done 
on any life form. For the purposes of this study, research ethics issues in policy will be defined as 
areas pertaining to medical or pharmaceutical research done on humans or whose results will 
affect humans. The federal government is the primary body through which research conduct is 
regulated; therefore, it is important to know what drives Congressional and federal agency 
interest in policy issues relevant to research ethics.  
As the fields of biomedical and pharmaceutical research expanded in the twentieth 
century following World War II, so too did a reckoning with their human impacts. Major 
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historical areas of research ethics include human subjects’ protection, the inclusion of relevant 
populations in research studies, and the extent of trial research necessary for an experimental 
product to be considered safe and effective. The United States’ modern history is rife with ethics 
violations in the name of research, as well as debates over proper ethical guidelines to govern 
research. The Tuskegee syphilis scandal from 1932 to 1972 saw an abuse of power by the U.S. 
National Public Health Service that took advantage of poor, uneducated black men in the rural 
South for forty years (Jones, 1993). It was not until 1993 that the Food and Drug Administration 
began requiring pharmaceutical testing on both men and women; thus, drugs approved prior to 
then were not necessarily tested for different side effects and proper dosage by sex (Hilts, 1993, 
p. B8). It was not until after the late 1950s and early 1960s, when the offspring of women who 
had taken the sedative Thalidomide while pregnant were born with significant developmental 
defects, that regulatory requirements for proving the safety of new drugs were put in place (Kim, 
2011). These and other examples are landmark events for a nation trying to balance the benefits 
of a biomedically advanced society with the proper ethics guidelines needed to regulate this 
progress.  
A large number of the most prominent policy events regarding research ethics were 
initially responses to tragedies or scandals. Some of these events are expounded upon in a later 
section of this thesis in order to illustrate this point. Large-scale catastrophes are considered a 
type of focusing, or triggering, event. Foundational literature in the field of agenda-setting, 
particularly Kingdon 1995, argues that focusing events distill abstract and complex issues into a 
discrete problem easily understandable to the public. Research ethics as a subject is not generally 
newsworthy, nor is it easily digestible for non-experts. The sudden introduction of an issue 
through a catastrophic event, usually carried out by the media, increases the probability that 
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people – either regular citizens or politicians – will consider the issue important (Vane and 
Kalvas, 2013). A shift in the priorities of the public and politicians can result in subsequent 
policy change to fix or ameliorate the problem. This historical trend implies that triggering 
events may be necessary for issues in research ethics to be included in the United States policy 
agenda. Such a system introduces a problematic cycle that affects the future of research ethics 
policy progress. As regulation increases, the likelihood and severity of triggering events 
decreases, thus decreasing political attention given to research ethics issues. In periods of wide 
deregulation, there is currently no strong opposition to important policy being taken away. In the 
absence of a steady presence advocating for responsible and modern research ethics policy, the 
United States is doomed to a cycle in which no proactive and progressive policy is made.  
There is a need to increase proactive research ethics advocacy at the federal level in order 
for progress in research ethics policy to continue. As a policy area, bioethics issues are blended 
into health and STEM advocacy work. While institutions of higher learning, medical groups, and 
departments of health and human services from the fifty states all make their voices heard in 
research ethics policy debates, each of these entities has a myriad of other policy concerns that 
overlap with and take priority over support for stringent ethics requirements. These often include 
financial interests and efficiency of the research process. Research ethics issues must compete 
for prioritization with often more lucrative or otherwise advantageous focus areas, like increased 
research funding and changes to the national healthcare policy. Moreover, it is unlikely that 
policymakers will turn their attention to research ethics unless concern arises through a 
triggering event. As such, this thesis argues the need to establish an independent non-
governmental body whose sole purpose is to provide sound policy recommendations when they 
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are needed, in order to improve the federal government’s response to triggering events and serve 
as a cautionary voice during waves of widespread deregulation.  
While a majority of regulations on research come from federal agencies like the Health 
and Human Services Department and the Food & Drug Administration, mandates to do this work 
often come from Congress. As the legislative branch is generally the most responsive to 
advocacy and lobbying efforts (especially in the wake of a triggering event), this thesis focuses 
on the Congressional side of research ethics policymaking. In order to justify the need to 
establish an independent advocacy body that reduces the dependence of research ethics policy 
progress on these major triggering events, this thesis seeks to create a bird’s-eye view of major 
policy action relevant to research ethics in the United States Congress from 1905 to the present, 
beginning with the Pure Food and Drug Act. In addition, this thesis highlights the obstacles 
facing advocacy efforts in the research ethics arena and explore possible remedies.  
Background 
The formal field of bioethics is quite young, having only been established as an academic 
discipline in the 1960s and 1970s (Callahan, 2012). Prior to its founding, religious leaders, 
particularly Catholics, were the primary voices of morality in scientific and medical issues. 
Bioethics is now an interdisciplinary field comprised of ethicists, scientists, physicians and other 
medical practitioners, lawyers, and many others. This growth resulted from the explosion of 
biomedical advancements that occurred during and following World War II. Inventions such as 
the cardiac pacemaker, dialysis machines, and oral contraceptives spurred a larger conversation 
about the proper limits to medical interventions as human capacity to alter nature’s course 
rapidly expanded. As is aptly stated by Lee and McCarty, “Scholars have debated whether 
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bioethics is a discipline with its own methods and theoretical grounding, a multidisciplinary field 
bringing various professional perspectives to bear on particular types of problems, a set of 
problem-solving skills to resolve moral disagreements, or something else entirely” (Lee and 
McCarty, 2016, p.19). For the purposes of this paper, it is immaterial whether bioethics meets a 
strict definition of an academic discipline, beyond an acknowledgement that most people 
currently interested in the field are academics. Bioethics, and research ethics in particular, is 
relevant to the current investigation as a body of knowledge crucial to the development of 
appropriate regulations that govern scientific research in the United States.  
Research ethics is one of three major branches of bioethics which, broadly defined, is the 
study of ethics within the biological sciences. The other two branches are medical ethics and 
public health ethics. The former is concerned with an array of issues within medical practice, 
such as the doctor-patient relationship and abortion. The latter deals with ethical dilemmas in the 
public health sphere. Research ethics, predictably, confronts ethical issues in the course of all 
kinds of research, including academic and pharmaceutical. Though research ethics primarily 
focuses on conduct during biological and biomedical research, it includes any research involving 
human or nonhuman subjects.  
While the advent of bioethics is typically attributed to the rapid biomedical advancements 
brought about by World War II, one can argue that specifically research ethics as a policy issue 
actually began at the beginning of the twentieth century during the Progressive Era. The passage 
of the Pure Food and Drug Act of 1906, which banned the sale of adulterated or misbranded food 
and drugs – terminology that includes untested drugs – was part of a larger Progressive 
movement that encouraged increased use of the scientific method. This law was the first in the 
United States to require that pharmaceutical drugs must be labelled with their ingredients, and 
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the first major step in encouraging transparency in the pharmaceutical research industry. The 
Pure Food and Drug Act was passed in part due to media attention around Upton Sinclair’s The 
Jungle, which revealed the grossly unsanitary conditions in the meat industry (U.S. Food & Drug 
Administration, 2019). As the twentieth century progressed, a number of triggering events like 
the publishing of The Jungle led to research ethics policy reforms.     
The vast majority of human subjects research that is federally funded is now under 
the jurisdiction of the Federal Policy for the Protection of Human Subjects, also known as 
the Common Rule (45 C.F.R. § 46). The Health and Human Services Office of Human 
Research Subjects Protections states that the Common Rule governs all research done 
under the auspices of twenty different federal agencies, including the Department of Health 
and Human Services, the Department of Energy, the Department of Defense, and the 
National Science Foundation. The Food and Drug Administration promulgates different 
regulations, which are nevertheless required to align with Common Rule regulations when 
permitted by law (21 C.F.R. § 50).  
 However, agencies derive rulemaking power from the United States Congress, which 
creates agencies and can pass laws “that more specifically [direct] an agency to solve a 
particular problem or accomplish a certain goal” (Office of the Federal Register, 2020). For 
example, the Food, Drug, and Cosmetic Act, passed by Congress in 1938, gave the FDA 
power to ensure the safety of food, drugs, medical devices, and cosmetics (Food, Drug, and 
Cosmetic Act of 1938). Therefore, though research is most directly regulated by agencies, 
policy action starts in Congress.  
The question then arises: Under what conditions does a narrow issue like research 
ethics attract the attention of members of Congress? The academic field of agenda-setting 
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within political science seeks to answer this. There are different common themes in how a 
policy issue gets on the federal agenda, one of which is the occurrence of triggering events, 
also known as focusing events. Birkland, referencing his own previous work and the 
landmark 1995 work by Kingdon, defines a focusing event as “an event that is sudden; 
relatively uncommon; can be reasonably defined as harmful or revealing the possibility of 
potentially greater future harms; has harms that are concentrated in a particular 
geographical area or community of interest; and that is known to policy makers and the 
public simultaneously” (Birkland, 1998, p.54). This definition has remained roughly 
consistent since the 1990s, and is applied in the next section of this paper.  
 As stated in Birkland’s definition, focusing events drive policy change by 
magnetizing attention and harshly illustrating an issue that could be addressed through 
policy. Examples of triggering events include the aforementioned Tuskegee syphilis 
scandal, which led to the creation of the Belmont Report and subsequent Federal Policy for 
the Protection of Human Subjects. This paper demonstrates how focusing events have been 
a prominent driver of research ethics policy creation throughout the twentieth century, the 
limitations of such a system going forward, and the resultant necessity for the 
establishment of an independent non-governmental organization as a new driver of 







Analysis of Significant Historical Policy Events 
Nazi Experimentation on Prisoners during the Holocaust   
One of the first formative series of events for American bioethics happened on European 
soil. The Holocaust comprised many of the most horrific human rights abuses in modern 
Western history; however, the torture carried out by Nazi doctors in the course of 
experimentation on prisoners in concentration camps is perhaps one of the worst of these 
atrocities. Nazi scientists and doctors, based on their belief in Social Darwinism, racial hygiene, 
and Aryan racial superiority, designated Jews, homosexuals, Romani people, and other 
populations as “subhuman,” and thus eligible for experimentation (Seidelman, 1996). However, 
this belief system was not developed in a vacuum. Eugenics and racial hygiene were taught at 
many of the top medical schools in the world, and as Seidelman states, “Many academic and 
scientific institutions which contributed to the evils of the Third Reich were the same 
organizations which had earlier helped give birth to modern medical science and medical 
education” (Seidelman, 1996, p.1463). Therefore, it is clear that unethical practices and beliefs of 
varying degrees had been woven into the fabric of research conduct from the outset. Experiments 
covered a number of subjects, notably “exposure to low pressure, cold, and sea water; injection 
of infectious viruses into open wounds; mutilation and grafting of limbs; [and] development and 
application of efficient methods of large-scale extermination, genocide, and sterilization” (Ivy, 
1949, p.8).  
Though not officially adopted by any governments or international associations, the 
Nuremberg Code is widely considered to be one of the most influential documents in the history 
of bioethics (Shuster, 1997). It was the first in a cascade of international and domestic policy 
works that established rights for researchers and research subjects, and was intended to strike a 
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balance between encouraging scientific exploration and taking the proper precautions to ensure 
that research is conducted in an ethical manner. 
The Doctors’ Trial was conducted by American judges in Germany, and the Nuremberg 
Code was essentially an American creation. However, this first modern instance of a scandal 
with implications for research ethics belies the general assumption that tragedy necessarily 
begets domestic legislative action. Though many Americans were made aware of the potential 
ethical problems within research, it was not generally thought that the same types of issues 
would be present in the United States. Despite wide publication of the horrors of Nazi 
experimentation on prisoners during the Holocaust, American scientists largely dismissed the 
possibility that they too could be guilty of unethical conduct. The scandal did not inspire closer 
inspection of domestic research practices; this implies that is more likely to get on the 
Congressional agenda if the unethical practice harms Americans.  
 
Elixir Sulfanilamide Disaster 
 At the start of the twentieth century, drug production in the United States was regulated 
by the Pure Food and Drug Act of 1906. This legislation, whose passage was driven in large part 
by a series of sensational news articles detailing the corruption within the beef industry and the 
publishing of Upton Sinclair’s The Jungle, was the first federal law to enforce food and drug 
quality (Pure Food and Drug Act 2014). A prominent example of Progressive Era legislation, the 
Pure Food and Drug Act outlawed “adulterated or fraudulently labelled food or drugs” (Pure 
Food and Drug Act 2014). However, it did not require that pharmaceutical companies prove that 
their drugs were safe for consumption, nor that companies list all of a medication’s ingredients 
on their labels (Campbell, 2008). This glaring gap in requirements for clinical research came to 
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the attention of the American public in 1937, when elixir sulfanilamide, a liquid form of the 
breakthrough drug sulfanilamide, was put on the market (Campbell, 2008).  
 According to Campbell 2008, sulfanilamide effectively – and safely – combats numerous 
infections, including gonorrhea and strep throat. However, it was only sold in tablet or capsule 
form prior to the advent of elixir sulfanilamide. The Samuel E. Massengill pharmaceutical 
company found that sulfanilamide dissolves in diethylene glycol, a derivative of petroleum. At 
the time this discovery was made, it was known that diethylene glycol had been proven fatal in 
animals; it is unclear whether or not the Massengill company was aware of this, but they did not 
do any safety testing of their own on humans, and government approval was not required to 
market a drug in 1937 (Campbell, 2008).  
 Within two months, one hundred and seven people who had ingested elixir sulfanilamide 
had died (Campbell, 2008). Doctors reported the fatalities to the American Medical Association 
due to the limited oversight abilities of the FDA, which had only been created six years prior in 
1931 (Campbell, 2008). The AMA, after conducting independent tests of elixir sulfanilamide 
because the drug’s ingredients were not listed on the bottle, publicized the inclusion of 
diethylene glycol in the medication (Campbell, 2008). This rapid period of mobilization 
following an extraordinary number of deaths in a short period of time effectively pushed the 
federal government into action.  
 Due to lack of legal requirements to prove drug safety, list ingredients on the drug bottle, 
or gain government approval before placing a drug on the market, the FDA fined the Samuel E. 
Massengill company twenty-six thousand dollars over their misuse of the technical word "elixir," 
which denotes a liquid containing alcohol (Campbell, 2008). The election of Franklin D. 
Roosevelt brought about favorable political conditions for FDA chief Walter Campbell to 
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capitalize on the tragedy and pressure lawmakers to pass the Food, Drug, and Cosmetic Act, 
which had not advanced in Congress since its introduction in 1933 (Campbell, 2008). The new 
law empowered the FDA to require a new medication be proven safe for humans before it is 
placed on the market "and" that people obtain a prescription from a licensed physician before 
being allowed to purchase a drug (Campbell, 2008).  
 The elixir sulfanilamide disaster changed the way the United States understood 
pharmaceutical research and development. Following on the heels of Progressive Era consumer 
protection movements, it revealed the lack of standards for drug safety, and the consequent 
dangers to the public. The episode underscored the idea that clinical research is not only an 
essential component of drug development, but that testing for testing the safety of 
pharmaceutical products is necessary to protect the public.  
 
Thalidomide Tragedy  
 Thalidomide was a drug marketed in the 1950s as a non-toxic sedative that also helped 
with morning sickness. It was put on the market in 1957 in Germany by Chemie Grunenthal, 
under the name Contergan (Botting, 2015).  Though clinical research for the drug’s safety had 
been investigated in animals, thalidomide had not been tested on pregnant animals (Botting, 
2015). By the early 1960s it was marketed in 46 countries, not including the United States.  Dr. 
Frances Kelsey, an FDA pharmacologist, denied the company’s approval application due to their 
failure to prove the safety of the drug for humans.  She was authorized to do this under the now-
passed Food, Drug, and Cosmetics Act of 1938. Regarding the thalidomide applications for 
approval in the United States that began in 1960, Kelsey stated that “deficiencies in all areas 
were found during the initial review and in several subsequent resubmissions” (Botting, 2015).  
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 Kelsey’s concern was well-founded; from thalidomide’s entrance into the German market 
in 1957 to 1961, evidence mounted from numerous independent doctors and researchers that 
thalidomide was not non-toxic, as was asserted in the original clinical papers published by 
researchers from Chemie Grunenthal, thalidomide’s manufacturer (Botting, 2015). Anecdotal 
reports of peripheral neuritis in patients taking thalidomide, as well as an “epidemic of particular 
fetal abnormalities” without an immediate explanation, led to scrutiny of the drug (Botting, 
2015). It was based on the evidence of peripheral neuritis that Dr. Frances Kelsey and the FDA 
blocked the sale of thalidomide in the United States (Adler, 1994). A startling number of 
children in Germany were born with a condition known as “phocomelia,” a shortening or 
absence of the long bones in the arms or legs that produced seal-like limbs (Botting, 2015).  
 It became apparent that the original toxicity testing of thalidomide was done with a 
version that was poorly water-soluble; therefore, the drug was observed to be non-toxic because 
it was not actually being absorbed by the body in significant amounts (Botting, 2015). The 
version of thalidomide that Chemie Grunenthal elected to sell was “microfined thalidomide 
mixed with sugar solution,” which is water-soluble and was later found to be highly toxic in 
mice (Botting, 2015). The superficiality and negligence of the initial clinical testing for 
thalidomide, and the bold claims of non-toxicity stemming from it, were made even more 
insulting by the choice to use the results to sell what was essentially a different product.  
 American citizens, particularly pregnant women and their children, were largely saved 
from the catastrophic effects of thalidomide consumption by the ability of the FDA to refuse 
approval of drugs for which safety had not been sufficiently demonstrated. These regulations did 
not exist at the time in the United Kingdom, Germany, and many other countries, which led to 
widespread consequences (Botting, 2015). However, approximately 20,000 Americans were still 
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given thalidomide, as free samples of the drug were distributed to doctors while the FDA was 
deliberating on its approval application, and a few cases of fetal abnormalities did occur 
(Botting, 2015). This loophole was subsequently closed by the 1962 Kefauver-Harris 
Amendment to the Food, Drug, and Cosmetics Act, which empowered the FDA to monitor all 
stages of drug development prior to its use in humans (Botting, 2015). It also required that 
pharmaceutical companies prove not only that a drug is safe, as was mandated by the original 
Food, Drug, and Cosmetics Act, but also effective (U.S. Food & Drug Administration, 2012). 
 As stated by Botting 2015, “No drug has had a greater effect than thalidomide on the 
extent and intensity of the preclinical investigation of potential medicines required by the 
regulatory authorities [globally].”  The thalidomide tragedy evidenced a number of shortcomings 
in clinical research guidelines that had not previously garnered the attention of politicians, 
despite their presence throughout the short history of modern drug development.  
 
Tuskegee Syphilis Study  
In 1932, the United States Public Health Service began what became a longitudinal study 
in which they observed the progression of syphilis in four hundred black sharecroppers in rural 
Macon Country, Alabama (Brandt, 1978). At this point in history, scientists believed that 
diseases expressed themselves differently in different races, and such was the justification for the 
experiment. The research participants, who contracted syphilis independently, were not informed 
of the experiment, and were instead told that the National Public Health Services was going to 
check on them periodically and provide free treatment in exchange for their involvement. A 
study of this design was not uncommon in the 1930s. As aptly stated by David M. Smolin, “If 
the Tuskegee study had ended after that first year, it would not have been a historically 
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significant event, but merely one of innumerable examples of a broader trend in which 
physicians and researchers misinformed patients and research subjects” (Smolin, 2012). At this 
point in history, paternalistic conduct was the modus operandi towards the entire population, 
regardless of patients’ race or gender; professionals in biomedical fields were not expected to 
consult with their patients, and in many cases patients and research subjects did not want to have 
full knowledge of treatment protocols, risks of treatment, or their prognoses. However, the 
Tuskegee syphilis study extended well into a time when the ubiquity of paternalism had passed.  
The Tuskegee syphilis study comprised multiple ethical violations. Beyond a complete 
absence of informed consent from research participants, the investigators failed to treat the men 
with penicillin after its FDA approval in 1944 as an effective solution to syphilis. By the time the 
study was halted, at least 28 of the subjects had died from syphilis (Brandt, 1979). The study 
continued for 40 years until 1972, when it caught the attention of the media and became widely 
publicized for its gross ethical abuses. As stated by Adashi et al., “the Tuskegee Syphilis Study 
made it plain that the moral foundation of human subject research was in desperate need of 
repair,” and international nonbinding documents like the Nuremberg Code and the Declaration of 
Helsinki were not sufficient to guarantee ethical research conduct in the United States (Adashi et 
al., 2018). The conduct of the National Public Health Service caught the attention of Senator Ted 
Kennedy, who began conducting hearings to investigate the extent of the damage done. This 
effort led to passage of the National Research Act of 1974, which established the National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 
commonly known as the Belmont Commission (Blustein, 2005). In 1978, the Commission 
produced the Belmont Report, the first document in the United States establishing foundational 
ethical principles for the governance of human subjects research. According to Blustein (2005),  
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“[The Belmont Report] argues that a fundamental distinguishing characteristic of 
research is generalizability. Scientific research is conducted to acquire knowledge that is 
accessible to all. That knowledge is a public good. Because research subjects assume risk in 
order to generate good for all, different (and higher) ethical standards apply in science than do in 
everyday life” (p.826)  
The Report outlines three guiding principles significantly inspired by the Nuremberg 
Code and the Declaration of Helsinki: respect for persons, beneficence, and justice. Respect for 
persons is a recognition of research subjects’ autonomy and valuing of wellbeing; it is from this 
tenet that the concept of informed consent arises (Blustein, 2005). Beneficence is a recognition 
that “risk is only justified in proportion to the expected benefits [of research]” (Blustein, 2005). 
This calculation is complex and varies significantly between unique research situations, but 
essentially requires a prioritization of risk reduction and an examination of how worthwhile a 
proposed research project truly is. The final principle, justice, refers to “the fair and equitable 
distribution of research benefits and burdens” (Blustein, 2005). The Belmont Report calls 
attention to the reality that, as evidenced by the Tuskegee scandal, “welfare patients, particular 
racial and ethnic minorities, or persons confined to institution are being systematically selected 
simply because of their easy availability, their compromised position, or their manipulability, 
rather than for reasons directly related to the problem being studied.” In other words, it is not 
ethical to take advantage of people’s lack of certain privileges for the sake of research. Choice of 
research subjects should be based in their population’s relevance to the research question, and 
the potential of their population to benefit from the knowledge resulting from the study.  
The Belmont Report, published in the Federal Register in 1979, revolutionized human 
subjects research conduct in the United States. Had it been in place prior to the Tuskegee study, 
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the men would not have been chosen based on their economic situation and lack of access to 
other medical care. If they had been chosen and fully informed of the researchers’ intentions, the 
men likely would not have given their consent. The study probably would not have proceeded at 
all, because risk to the subjects certainly outweighed the benefits of the knowledge gained.  
The Belmont Commission also released a recommendation for the creation of 
institutional review boards (IRBs), an integral part of ethics enforcement in human subjects 
research today. Requirements for IRB approval and the ethical tenets outlined in the Belmont 
Report were packaged together as a set of regulations governing research sponsored by the then-
present Department of Health, Education, and Welfare in 1981 (Blustein, 2005). Later, these 
regulations were modified and published as the Federal Policy for the Protection of Human 
Subjects, also known as the Common Rule (Blustein, 2005). The Common Rule remains the law 
of the land for ethical research conduct.  
 
Conclusions  
Discussed above are just a few of the historical examples from the twentieth century in 
which a lack of human subjects protections or due diligence in pharmaceutical research led to 
large-scale harm for the general populace. Other cases, such as that of the Jewish Chronic 
Disease Hospital cancer study in 19631, the Willowbrook hepatitis study from 1956 to 19712, the 
Monster Study of stuttering children in the 1930s3, and Cold War human radiation experiments4 
reinforce the idea that regulation of research is necessary to improve and maintain the ethical 
 
1 See Lerner (2004) for more information on the Jewish Chronic Disease Hospital cancer study  
2 See Rothman (1982) for more information on the Willowbrook hepatitis study  
3 See Silverman (1988) for more information on the Monster Study  
4 See Advisory Committee on Human Radiation Experiments (1996) for more information on the Cold War 
human radiation experiments  
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integrity of the research community. As such, it is worthwhile to investigate how advocacy for 
research ethics policy progress can be executed most effectively.
Obstacles to Proactive Policy Advocacy 
In the interest of preventing future ethics abuses in research, it would be preferable 
to shift to a more proactive model of policy advocacy.  Reasoning for this has both moral 
and practical dimensions. It is immoral that, historically, the United States has only pursued 
protective regulations following harm to American citizens that occurred because those 
protections did not exist. Academic work in the field of research ethics has become 
sufficiently sophisticated to where problems are recognized and addressed, and experts 
are available to help policymakers resolve holes in current regulations. Practically, the 
current reliance on triggering events is unsustainable; as regulation of research increases, 
potential for gross ethical violations decreases, therefore lowering the probability that 
another triggering event will occur. This cycle outlaws the worst of ethics abuses but leaves 
more systemic and complex issues, like lack of inclusion of underrepresented groups in 
research that would otherwise benefit them, intact. Following this trend, the United States 
is at risk of slowing progress in research ethics policy, barring increased involvement from 
interest groups for whom research ethics is not a top priority. Though individual entities 
conducting research may have their own ethical conduct standards that are more rigorous 
than the federal regulations of the time, they have little to gain by advocating for these 
standards to become blanket laws set by the government. Lack of stricter formal 
regulations allows individual entities to optimally craft standards for their own operations.  
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Shifting to a more proactive research ethics policymaking environment would be 
difficult, as the obstacles are manifold. No major advocacy organizations are specifically 
devoted to this issue; research ethics is often a mid- to low-level policy priority for 
biomedical and academic groups. This is evidenced by the groups who responded to the 
notice of proposed rulemaking that preceded the final version of the 2017 revision of the 
Common Rule. Commenters representing organizations primarily worked for institutions 
of higher learning, national scientific and medical associations, and health-related state 
agencies. Organizations that are specifically committed to research ethics, such as private 
IRB companies, also shared their input on the proposed regulations, but these were a small 
minority of overall submissions.  
For interest groups like academic institutions and biomedical groups whose policy 
concerns are wide-ranging, commenting on proposed regulations is an inexpensive way to 
make their preferences heard. It has also proved to be an effective strategy, as those who 
comment early in the commenting period often succeed in influencing the content of the 
final rule (Naughton et al., 2009). However, advocacy on Capitol Hill takes time and 
monetary investment in the form of a dedicated governmental relations professional or 
team. As a result, niche issues related to research ethics are often deprioritized in the 
interest of more ostensibly pressing issues. For example, research institutions may have an 
interest in diversifying the pool of human research subjects participating in their research, 
but may put it on the back burner while focusing their efforts on obtaining better tax 
benefits in a bill set to pass that session.  
One type of interest group frequently working in the research ethics policy space is 
associations of people with personal stakes in the future and integrity of research, like the 
19 
 
Cystic Fibrosis Foundation or the National Organization for Rare Disorders (both of whom 
have commented on the notice of proposed rulemaking regarding the 2017 revision to the 
Common Rule). These groups stand to benefit from increased research quality. For 
example, the National Organization for Rare Disorders may represent subpopulations with 
disorders that affect people of many different racial backgrounds. The organization may 
then be incentivized to use resources to advocate for stronger requirements for diversity in 
clinical trial research subjects, given that disparities in how people from different racial 
backgrounds metabolize medications is well documented (Wood and Zhou, 1991; Johnson, 
1997; Xie et al., 2001). However, this type of advocacy group may also prioritize expedient 
research in order to get its members help more quickly. While there is an ethical debate 
over the proper balance between benefits of faster drug approval and maintaining the high 
quality of research, organizations of this ilk are not sufficient to establish a balanced 
advocacy push in the research ethics policy area. There is consistent potential for these 
groups’ other interests to overshadow or influence their stance on ethics issues. 
Another potential roadblock is that an advocacy group specifically devoted to 
elevating ethical conduct in the course of research would necessarily need to be comprised 
at least largely of academic experts at its inception. This is a challenging kind of policy to 
navigate, as ethics concerns frequently oppose arguments for faster approval of research 
protocols and new clinical drugs. The latter is especially difficult ground, given that there 
are many people who suffer from medical issues that have yet to be cured or for which 
current treatment options could be more effective or less deleterious to quality of life. 
Given these issues, a grassroots swelling of support for pure research ethics advocacy is 
extremely unlikely. People generally want easier access to health resources and less 
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bureaucratic red tape, both of which could be construed as parts of the research ethics 
advocacy mission. It would therefore require experts in the field to form a group based in 
the formal studies of ethics and various research disciplines, in addition to community 
stakeholders, to comprise a starting group.  
Advocacy organizations in the research ethics policy space must also deal with 
political barriers. Health care and funding for research and development frequently 
overshadow research ethics in party platforms. The finite amount of resources and political 
capital these groups possess have higher potential return in such areas. The official party 
platforms are just one way for an issue to get on legislators’ radars, and perhaps not the 
most effective way, but platforms are inarguably a major outward-facing expression of a 
political party’s values. The niche nature of research ethics means that visibility through 
this medium is unlikely. In general, it is more politically advantageous for politicians to care 
in the wake of a negative event, as this makes them appear responsive to citizen concerns. 
As was mentioned previously, this avenue for attention is becoming even less promising as 
protective regulations increase. The primary issues within research ethics now, such as 
effectiveness of informed consent documents, diverse population samples in research 
subject pools, and the importance of cultural proficiency, will not generate the same 
amount of media attention and subsequent investment of political capital as historical 
scandals did (Bloswick and Skowron, 2015; Quinn et al., 2013).  
 The people who are negatively affected by today’s suboptimal research practices 
are also typically not people most likely to inspire national sympathy. People who 
participate in research and thus are harmed by ethical violations in the course of research 
often are not privileged (Quinn, 2013). It is likely that a paid research study will mostly 
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attract subjects who need the money. Likewise, patients with an ailment not yet cured are 
more likely to volunteer themselves for a clinical trial. Thus, these people are in 
compromised positions; they could stand to benefit from the results of the research in 
which they are partaking or may be compensated for their time with a sum of money 
relatively large for them. While these realities may make participation worthwhile to the 
individual subject, it does not absolve researchers of imperfect conduct or research design. 
Creating the Solution: An Evolving World of Research Ethics 
Advocacy  
Given the limitations discussed in the previous section, creating favorable shifts in 
research ethics advocacy appears to be a steep uphill battle. In fact, they evidence the need for a 
new strategy, one that may leverage some of the obstacles into strengths. The field of research 
ethics needs to establish an independent, nonprofit interest group if current and future issues are 
going to be handled more proactively.  
Currently, there is no law that mandates all research in the United States be regulated by 
the federal government; instead, only research that is federally funded is bound by these rules. In 
the case of research for the purpose of drug or medical device development, FDA regulations 
must be adhered to in order for the product to be approved. As a result, much privately funded 
research is not required to follow many of the federal agency regulations, though many entities 
like research universities voluntarily comply with Common Rule standards.  
Though most regulation of human subjects research occurs through the federal agencies, 
the impetus for policy change does not necessarily originate within the agencies or from the 
White House administration. People interested in instituting change within research conduct are 
22 
 
underutilizing the power of Congress to allow – or require – agencies to evolve their policies. It 
is necessary to expand advocacy efforts on Capitol Hill to ensure that policy work relevant to 
research ethics becomes more proactive, because the legislative branch is designed to be the 
most responsive to the concerns of domestic groups and United States citizens.  
 A dedicated advocacy group would meet several different needs currently lacking in the 
research ethics policy space. As was mentioned in prior sections, a central method by which 
individuals and organizations may provide their input on policy change is through commenting 
on new regulations being proposed by federal agencies. This is inherently a reactive practice, and 
necessarily limited to the topics which have already been deemed worthwhile by the federal 
government. One key advantage of outside advocacy organizations is the freedom to influence 
social and political conversations in order to promote whatever issues they see fit. This ability is 
key for an organization like a hypothetical research ethics interest group, as it would be 
attempting to garner attention for issues not currently being considered by policymakers. For 
example, only approximately 70% of human subjects research (not including clinical drug trials) 
is funded and therefore regulated by federal agency regulations (Gelsinger and Shamoo, 2008). 
An initiative to make all domestic research regulated by these rules, which would be a major 
policy shift likely protested by industry, would require a legislative lobbying effort by an interest 
group. Many other currently prominent issues within research ethics, like increased requirements 
for cultural proficiency of researchers with their human populations of interest, could also be 
navigated best through strategic political advocacy.  
 Another advantage that builds directly on the former is the ability of nonprofits to collect 
and then amplify the voices of individual citizens who have little political power as lone actors. 
This includes both academics with little experience in politics and anyone with a grassroots 
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interest in research ethics issues. Bioethicists focusing on research ethics may have an interest in 
influencing policy, but currently do not have an avenue for doing so besides providing comments 
on proposed agency regulations or other smaller-scale efforts. Bioethicists working collectively 
with public policy experts and governmental relations professionals would have a more direct 
line of communication with the federal government that conveys an intent for consistent 
advocacy across time.  
 As one of the missions of a research ethics advocacy group would be to empower human 
research subjects, this organization must not silo itself into only providing expert input on the 
legislative agenda. It should also mimic entities like the American Civil Liberties Union (ACLU) 
and National Association for the Advancement of Colored People (NAACP) in providing a place 
where individuals can gain assistance in learning their rights as research subjects and acting as a 
representative for them. This is a crucial service because federal agencies overseeing proper 
research conduct do not have sufficient resources to effectively enforce current regulations. A 
paper by Paul Gelsinger and Adil E. Shamoo states that, as of 2008, the Food & Drug 
Administration had only two hundred investigators for over 350,000 sites where clinical trials 
were being conducted; thus, problems are often reported to the FDA after research has already 
concluded (Gelsinger and Shamoo, 2008). If an independent research ethics group served as a 
resource for people who experience unethical practices, it could continually improve its 
understanding of regulatory areas most in need of improvement.  
 In addition, a research ethics advocacy organization would have the flexibility to form 
coalitions with the stakeholders currently doing advocacy work in this area – such as universities 
and medical interest groups – when interests align, and also to break with these organizations 
when their other interests outcompete the ideal policy outcome from a research ethics standpoint. 
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It is unlikely that the current stakeholders would react negatively to the creation of a research 
ethics group, as they are all interested in appropriate research conduct. Many medical schools 
and universities, which do have existing relationships in various forms with policymakers, house 
bioethics centers, and thus would likely partner with an independent organization on many 
issues. Coalition-building magnifies the influence of advocacy efforts and would be crucial in 
affecting positive change within research ethics policy issues.   
 One potential obstacle in the formation of a research ethics interest group is the typical 
hesitancy of academics to enter into the political sphere. Research is a time-consuming 
profession, and forays into politics require concerted effort over long periods of time to make an 
impact. Alternatively, some may feel that their energy is better spent influencing the general 
public’s views of human subjects research conduct and related topics. This is a legitimate 
potential issue regarding recruitment of experts to serve as policy resources, particularly given 
the relatively small size of the research ethics academic population. However, an interest group 
would not only be comprised of professional bioethicists, but also policy experts and 
governmental relations specialists that would apply academics’ knowledge to political advocacy. 
Furthermore, specialized knowledge in any field that affects the welfare of society, as is the case 
with research ethics, should not simply sit on the shelf.   
 Another concern is sources of funding for an advocacy organization, given that one of the 
major reasons for creating such a group would be to establish independence from larger entities 
with broad ranges of policy concerns. Like any nonprofit, a research ethics interest group will 
need to establish a development arm to drive donations from philanthropists. Efforts to generate 
interest from donors in research ethics, however, should not resort to scare tactics that demonize 
researchers. The express purpose of a research ethics organization would be to maintain and 
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improve the integrity of scientific research in the United States through proper regulation and 
accountability measures; initiatives that reduce trust in scientists would be counterproductive to 
this mission.  
 The question of funding is in part why an independent research ethics policy group would 
most organically stem from an existing entity, such as the Hastings Center, that already possesses 
a donor base. From this starting point, the organization could position itself as a resource for 
pharmaceutical companies, universities, and other businesses and institutions who conduct 
biological or biomedical research. A nonprofit advocacy organization focused on improving the 
integrity of the research process in an unbiased fashion would be a prime candidate for these 
businesses’ philanthropic arms. By leveraging a public image as a societal good to garner 
support from other stakeholders in the research ethics policy sphere, a research ethics policy 
group can establish a sustainable fundraising plan.  
 This financial relationship with research institutions and businesses and reputation as a 
reliable policy source may serve to blunt opposition to policy initiatives that the research ethics 
organization supports. It may foster more of a conversation about proper research ethics policy 
than an oppositional battle, in which the research ethics organization can advocate for more 
proactive policy. Such an arrangement will often benefit the research ethics organization, 
especially in its early years as it builds relationships and name recognition. However, there will 
still be topics on which stakeholders with other priorities and the research ethics policy group 
will differ. Among these will likely be issues with the potential to cost researchers more time or 
money without significant personal or organizational benefit. For example, pregnant women 
have been historically excluded from pharmaceutical and other biomedical research, resulting in 
a severe dearth of knowledge on how drugs affect them despite evidence that treatments affect 
26 
 
them differently (Ballantyne, 2019). Involving more pregnant women in research is complex and 
represents an added cost for pharmaceutical development, but it does not change the fact that this 
lack of knowledge endangers women who must take medications to address other conditions. 
Advocating for increased inclusion of pregnant women in biomedical research and providing 
insight on how to do so ethically may set a research ethics policy group against stakeholders 
reluctant to take on the challenge. However, this is exactly the kind of scenario that such a group 
would be created to address.  
Potential avenues of action for a research ethics advocacy organization are numerous and 
pursuing all of them from the outset would be unrealistic. However, it is clear that an interest 
group of this nature, regardless of its initial emphases, would fill a large gap in the advocacy 
space and have the ability to scale up its projects as resources permit.  
 
Conclusion 
Through the study of major research ethics policy events of the twentieth century, it is 
clear that most were preceded by triggering events, which Birkland defines as sudden events 
with concentrated harms that are known to politicians and the public simultaneously (Birkland, 
1998). In the case of research ethics, triggering events often serve to illustrate what was before 
an abstract, esoteric issue, and demonstrate the need for change to policymakers. This process 
followed the elixir sulfanilamide disaster, the Tuskegee syphilis scandal, and the human radiation 
experiments of the Cold War. Research ethics policy progress, particularly the gradual 
empowerment of the FDA and the creation of the Federal Policy for the Protection of Human 
Subjects (also known as the Common Rule), has greatly reduced the occurrence of grossly 
unethical conduct in human subjects research.  
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However, a decrease in the number of newsworthy ethics abuses in the course of research 
does not mean that all human subjects research in the United States is now effectively regulated. 
Issues such as the legitimacy of subjects’ informed consent to participate in a study and rigorous 
risk-benefit analysis of proposed research are examples of contemporary problems with potential 
policy solutions. It is also important to note that research ethics work is not the enemy of 
researchers; further refinement of IRB approval processes and the cutting back of unecessary 
bureaucratic red tape are also prominent issues in the research ethics space, as was evidenced by 
the attention given to those issues in the revision of the Common Rule in 2017.  
Research into agenda setting demonstrates that much federal policy in the United States 
is reactionary, particularly in fields that require understanding of technical knowledge. Research 
ethics suffers twice over from this perspective, in that a sophisticated understanding of it requires 
background in both hard science and ethics. The knowledge gap between experts in the research 
ethics field, other stakeholders, and policymakers must be bridged in order for policy change to 
originate from Congress.  
In the past, that bridging was motivated by a triggering event that compelled legislators to 
understand the issue at hand. As the potency and frequency of research ethics abuses wanes with 
time and increased regulation, something new must drive the bridging of the gap. The foundation 
of a nonpartisan, independent research ethics advocacy organization would best serve this 
function, providing unbiased information resources that current stakeholders in the research 
policy arena cannot. The basic tools and personnel for an advocacy organization are already in 
existence; this is a call for professionals who specialize in research ethics, whether in the legal, 
academic, medical, or other fields, to mobilize their knowledge for policy-oriented progress.  
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This thesis is also a building block for further research into possibilities for the union of 
bioethics and policy. While the intersection of bioethics and law is a lively field, application of 
bioethics to policy requires further development. Future agenda-setting analysis into the behavior 
of universities, research institutes, pharmaceutical companies, and other entities conducting 
human subjects research regarding research ethics regulation would greatly contribute to the 
research ethics policy knowledge base. In addition, comparative studies of advocacy in research 
ethics versus other niche policy areas requiring technical knowledge would help burgeoning 
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